⌘K

Login Start Free

Home/Filings/4/0001415889-25-023555

4//SEC Filing

Paolini John F. 4

Accession 0001415889-25-023555

CIK 0001730430other

View on SEC.gov Company Profile

Filed

Sep 2, 8:00 PM ET

Accepted

Sep 3, 4:48 PM ET

Size

26.2 KB

Accession

0001415889-25-023555

Insider Transaction Report

Form 4

Period: 2025-09-01

Kiniksa Pharmaceuticals International, plcKNSA

Paolini John F.

CHIEF MEDICAL OFFICER

Transactions

Exercise/Conversion
Class A Ordinary Share
2025-09-01+1,750→ 59,153 total
Tax Payment
Class A Ordinary Share
2025-09-01$33.49/sh−2,841$95,145→ 60,434 total
Exercise/Conversion
Class A Ordinary Share
2025-09-02+1,725→ 62,159 total
Award
Restricted Share Unit
2025-09-01+9,828→ 9,828 total
→ Class A Ordinary Share (9,828 underlying)
Award
Share Option
2025-09-01+39,364→ 39,364 total
Exercise: $33.49Exp: 2035-08-31→ Class A Ordinary Share (39,364 underlying)
Exercise/Conversion
Class A Ordinary Share
2025-09-01+1,624→ 60,777 total
Tax Payment
Class A Ordinary Share
2025-09-02$34.28/sh−835$28,624→ 61,324 total
Exercise/Conversion
Restricted Share Unit
2025-09-01−1,750→ 5,250 total
→ Class A Ordinary Share (1,750 underlying)
Exercise/Conversion
Restricted Share Unit
2025-09-02−1,725→ 0 total
→ Class A Ordinary Share (1,725 underlying)
Exercise/Conversion
Class A Ordinary Share
2025-09-01+2,498→ 63,275 total
Exercise/Conversion
Restricted Share Unit
2025-09-01−1,624→ 3,248 total
→ Class A Ordinary Share (1,624 underlying)
Exercise/Conversion
Restricted Share Unit
2025-09-01−2,498→ 2,497 total
→ Class A Ordinary Share (2,498 underlying)

Footnotes (7)

[F1]Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
[F2]The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2025.
[F3]The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2025.
[F4]The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024.
[F5]The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
[F6]The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
[F7]The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 2, 2021.

Documents

1 file

4
form4-09032025_080906.xmlPrimary

Issuer

Kiniksa Pharmaceuticals International, plc

CIK 0001730430

Entity typeother

Related Parties

1

filerCIK 0001741533

Filing Metadata

Form type: 4
Filed: Sep 2, 8:00 PM ET
Accepted: Sep 3, 4:48 PM ET
Size: 26.2 KB

View on SEC.gov